Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

TriMas Posts 14% Revenue Gain in Q2


(NASDAQ:TRS), a diversified manufacturer active in packaging, aerospace, and specialty products, reported Q2 2025 results on July 29, 2025. The company decisively outperformed analyst expectations for the period, driven by robust Aerospace growth, efficient operations, and the integration of recent acquisitions. Adjusted earnings per share reached $0.61 versus the expected $0.48. Revenue was $274.8 million, ahead of the $250.1 million GAAP consensus. The period showed strong year-over-year improvements in key profitability and cash flow metrics. Management increased its full-year 2025 sales and adjusted earnings guidance, reflecting both execution and confidence in its outlook, while noting some end-market risks remain.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

TriMas is an industrial company specializing in the design and manufacture of products for global packaging, aerospace, and specialty applications. Its main segments include Packaging, which produces closures and dispensing pumps; Aerospace, focused on fasteners and precision components for aircraft; and Specialty Products, which offers high-pressure cylinders and related goods. The company is known for supplying critical components to sectors such as consumer goods, medical, and defense, combining manufacturing scale with tailored engineering capabilities.

Continue reading


Source Fool.com

Trimas Corp. Aktie

28,20 €
-0,70 %
Heute erleidet Trimas Corp. einen kleinen Verlust von -0,70 %.
Mehrere Buy-Einschätzungen dominieren bei Trimas Corp. ohne Sell-Gegenstimmen.
Eine Steigerung von über 20% ist für Trimas Corp. möglich, angesichts eines Kursziels von 38 € gegenüber 28.2 €.

Kommentare